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Over the past two decades, the progress in mo-
lecular genetics and neuropathology enabled a better 
understanding of the pathogenesis of neurodegenera-
tive disorders. The observation that abnormal protein 
accumulation is characteristic of a particular disease has 
led to a neuropathological classification according to the 
composition of the abnormal protein aggregates [1]. 
Several methods have been developed for the detection 
of these insoluble protein aggregates including, for in-
stance, dye binding assays and immunohistochemistry 
with proteinase K pretreatment [1]. Filter retardation 
assay is a simple and rapid method which detects pro-
tein aggregates formed either in vivo or in vitro, includ-
ing amyloid-beta/tau aggregates from Alzheimer’s dis-
ease (AD) [2–4] and polyglutamine expansion from Hun-
tington’s disease [5,6]. In this assay, ‘lysis buffer’-
resistant protein aggregates, but not soluble monomeric 
species, are retained by a cellulose acetate membrane 
and subsequently detected by immunoblotting. As load-
ing control, a ‘classical’ dot blot with either polyvinyli-
dene fluoride (PVDF) or nitrocellulose membranes is run 
in parallel with the same lysates. 
In contrast to polyglutamine expansion, tau and 
beta-amyloid, there are only few studies on using filter 
retardation assays for the detection of alpha-synuclein 
aggregates, which are characteristic of Parkinson’s dis-
ease (PD) and dementia with Lewy bodies (DLB) [7]. In 
addition, a full characterization of any filter-based assay 
for alpha-synuclein, including the effect of membrane 
composition, lysis procedure and antibodies has not yet 
been reported. We therefore set out the current study in 
which we characterize a vacuum-based 96-well format 
filter assay for the detection of aggregated alpha-
synuclein in human brain specimens. Frozen brain sam-
ples from neuropathologically confirmed cases of DLB, 
progressive supranuclear palsy (PSP) and AD were ob-
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tained from the Neuropathology Department of Angers 
(Dr Franck Letournel). Brain samples were lysed with the 
“Precellys 24™” tissue homogenizer (Bertin technolo-
gies, Cat# P000669-PR240-A, Montigny-le-Bretonneux, 
France) followed by a brief sonication (one minute, 5 
seconds on, 5 seconds off, amplitude 70%; VCX130 ultra-
sonic processor with a 6 mm probe, Sonics and Materi-
als, Newton, CT, USA) either in (i) radioimmunoprecipita-
tion assay (RIPA) buffer (Merck Millipore, Cat# 20-188, 
Molsheim, France) containing 2 mM orthovanadate 
(Sigma, Cat# S6505, Saint Quentin Fallavier, France), 1% 
(v/v) phosphatase inhibitor cocktail III (Sigma, Cat# 
P0044) and a protease inhibitors cocktail (Roche, Cat# 
14424700, Meylan, France) at 4°C; (ii) ‘Sodium dodecyl 
sulfate (SDS) buffer’ containing 1% (w/v) SDS, 2 mM 
orthovanadate (Sigma, Cat# S6505) and 1% (v/v) phos-
phatase inhibitor cocktail III (Sigma, Cat# P0044); (iii) 
‘Urea buffer’ containing 7 M urea (Sigma, Cat# T7875), 2 
M thiourea (Sigma, Cat# L3771), 4% (v/v) CHAPS (Sigma, 
Cat# C3023), 2 mM orthovanadate (Sigma, Cat# S6505), 
1% (v/v) phosphatase inhibitor cocktail III (Sigma, Cat# 
P0044) and a protease inhibitors cocktail (Roche, Cat# 
14424700). Lysates were centrifuged at 10,000 x g for 5 
minutes; supernatants were recovered and protein con-
centration determined using the Pierce BCA Protein 
Assay Kit (ThermoFisher Scientific, Cat# 23227, Saint 
Herblain, France) along with the Varioskan™ multimode 
microplate reader (ThermoFisher Scientific, Cat# 
VL0L00D0); samples lysed in urea buffer were diluted 5 
times for compatibility with the BCA assay 
(https://assets.thermofisher.com/TFS-Assets/LSG/
Application-Notes/TR0068-Protein-assay-compatibility.pdf). 
Twenty µg of these supernatants were subjected to 
vacuum filtration through a 96-well dot blot apparatus 
(Bio-Rad, Cat# 1706545, Marnes-la-Coquette, France) 
with 0.45 µM pore size cellulose acetate (Sterlitech, Cat# 
CA0453001, Kent, USA), nitrocellulose (ThermoFisher 
Scientific, Cat# 77010) or PVDF membranes (Ther-
moFisher Scientific, Cat# 88518). The resultant mem-
branes were blocked for one hour at room temperature 
in Tris-buffered saline (TBS, Sigma, Cat# T5912) with 
0.1% (v/v) Tween-20 (Sigma, Cat# P1379) and 5% (w/v) 
non-fat dry milk, then incubated overnight at 4°C with 
the primary antibodies listed in Table 1. Bound antibod-
ies were detected with horseradish peroxidase-
conjugated anti-rabbit (Life technologies Cat# 31460, 
diluted 1:5,000) or anti-mouse antibodies (Sigma, Cat# 
A9044, diluted 1:5,000) and visualized by enhanced 
chemiluminescent detection (SuperSignal™ West Pico 
PLUS Chemiluminescent Substrate, ThermoFisher Scien-
tific, Cat# 34580). Oligomeric aggregates of alpha-
synuclein, which were obtained by incubating monomer-
ic recombinant alpha-synuclein (Sigma, Cat# 575001) in 
phosphate-buffered saline under agitation at a concen-
tration of 10 mg/mL at 37°C for one week, served as a 
control [8]. 
When cellulose acetate membranes were used, re-
combinant oligomeric alpha-synuclein and DLB lysates 
were barely or not detected by two of the total alpha-
synuclein antibodies (Syn211 and Syn-1), regardless of 
the lysis procedure (Figure 1a). In contrast, MJFR1 anti-
body efficiently detected both oligomeric alpha-
synuclein and aggregated alpha-synuclein from RIPA-
lysed DLB samples (Figure 1a). No specific signal was 
observed with this antibody when DLB samples were 
lysed with SDS or urea buffers (Figure 1a). Two of the 
phosphospecific antibodies (EP1536Y and to a lesser 
extent pSyn#64) detected aggregated alpha-synuclein in 
RIPA-DLB lysates. No signal was observed when PSP and 
AD lysates were filtered and analyzed with either MJFR1 
or EP1536Y antibody. These findings show that sample 
lysis with RIPA sample lysis together with MJFR1 and/or 
EP1536Y immunoblotting is the most specific and repro-
ducible approach. We therefore used these two antibod-
ies and RIPA-lysed samples to perform additional dot 
blots with PVDF or nitrocellulose membranes, that could 
serve as a loading control. The results show that PVDF 
achieved better reproducibility and specificity for the 
detection of total and phosphorylated alpha-synuclein 
than nitrocellulose membranes (Figure 1b). 
 
 
Table 1. Alpha-synuclein and phospho-alpha-synuclein antibodies used in the current study. 
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Figure 1. Results from the filter trap and dot blot assays. (a) recombinant oligomeric alpha-synuclein (oligo) and samples from DLB, PSP 
and AD brains lysed in RIPA, SDS and Urea buffers were subjected to vacuum filtration through a 96-well dot blot apparatus with an 
acetate cellulose membrane; immunoblotting (IB) was then performed with 3 different antibodies to total alpha-synuclein (MJFR1, Syn-
1 and Syn211) and 3 antibodies specific for the phosphorylated form of the protein (EP1536Y, pSyn#64 and Phospho S129). (b) recom-
binant oligomeric alpha-synuclein (Oligo) and RIPA-lysed samples from DLB, PSP and AD brains were subjected to vacuum filtration 
through a 96-well dot blot apparatus with a PVDF or a nitrocellulose membrane ; immunoblotting (IB) was then performed with MJFR1 
or EP1536Y antibodies. Results shown are representative of 3 to 5 independent experiments. 
 
The results presented here, although preliminary, 
provide the basis for reproducible and specific detection 
of pathological alpha-synuclein in diseased brains using a 
filter trap assay. We show that the selection of primary 
antibody and lysis buffer has important effects on the 
performance of the assay. As an optimized protocol, we 
suggest that brain homogenates should be lysed in RIPA 
buffer and that immunoblotting should be performed 
with MJFR1 for the detection of total alpha-synuclein 
and EP1536Y for the detection of the phosphorylated 
form of the protein (a step by step standard operating 
procedure is provided as supplementary material). Ow-
ing to the high-throughput capability of the filter trap 
assay, such an approach is not only potentially interest-
ing for detecting aggregated alpha-synuclein in post 
mortem brain samples but also in the peripheral nervous 
system of living PD patients in order to develop original 
biomarkers of the disease [9]. 
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